0000885725false00008857252026-11-192026-11-190000885725us-gaap:CommonStockMember2026-11-192026-11-190000885725bsx:SeniorNotedue2027Member2026-11-192026-11-19
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
_____________________________________________________________________
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
_____________________________________________________________________
Date of Report (Date of earliest event reported): November 19, 2026
BOSTON SCIENTIFIC CORPORATION
(Exact name of registrant as specified in its charter)
| | | | | | | | | | | | | | | | | | | | |
| Delaware | | 1-11083 | | 04-2695240 |
| (State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
300 Boston Scientific Way, Marlborough, Massachusetts 01752-1234
(Address of principal executive offices) (Zip Code)
(508) 683-4000
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: | | | | | |
| ☐ | Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
| | | | | | | | | | | | | | |
| Title of each class | | Trading Symbol | | Name of each exchange on which registered |
| Common Stock, $0.01 par value per share | | BSX | | New York Stock Exchange |
| 0.625% Senior Notes due 2027 | | BSX27 | | New York Stock Exchange |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 1.01 Entry into a Material Definitive Agreement.
On November 19, 2026, Boston Scientific Corporation (the “Company”) entered into an Underwriting Agreement (as supplemented by the Terms Agreement, also dated November 19, 2026, the “USD Underwriting Agreement”), among the Company and the representatives of the several underwriters named in the USD Underwriting Agreement (the “USD Underwriters”), in connection with the pricing of $3,000,000,000 aggregate principal amount of the Company’s U.S. dollar-denominated senior notes (the “USD Offering”). Pursuant to the USD Underwriting Agreement, the USD Underwriters agreed to purchase $1,000,000,000 in aggregate principal amount of 5.375% Senior Notes due 2029, $750,000,000 in aggregate principal amount of 5.500% Senior Notes due 2031, $750,000,000 in aggregate principal amount of 5.750% Senior Notes due 2033 and $500,000,000 in aggregate principal amount of 5.875% Senior Notes due 2036 (collectively, the “USD Notes”).
In addition, on November 19, 2026, the Company, as guarantor, and American Medical Systems Europe B.V. (“AMS Europe”), its indirect wholly owned finance subsidiary, as issuer, entered into an Underwriting Agreement (as supplemented by the Terms Agreement, also dated November 19, 2026, the “Euro Underwriting Agreement” and, together with the USD Underwriting Agreement, the “Underwriting Agreements”), among the Company, AMS Europe and the several underwriters named in the Euro Underwriting Agreement (the “Euro Underwriters” and, together with the USD Underwriters, the “Underwriters”), in connection with the pricing of €4,250,000,000 aggregate principal amount of AMS Europe’s euro-denominated senior notes (the “Euro Offering” and, together with the USD Offering, the “Offerings”). Pursuant to the Euro Underwriting Agreement, the Euro Underwriters agreed to purchase €500,000,000 in aggregate principal amount of Floating Rate Notes due 2028 (the "Floating Rate Notes"), €500,000,000 aggregate principal amount of 3.875% Senior Notes due 2028, €750,000,000 in aggregate principal amount of 4.125% Senior Notes due 2030, €750,000,000 in aggregate principal amount of 4.500% Senior Notes due 2034, €1,000,000,000 in aggregate principal amount of 4.750% Senior Notes due 2038 and €750,000,000 aggregate principal amount of 5.125% Senior Notes due 2046 (collectively, with the Floating Rate Notes, the “Euro Notes” and, together with the USD Notes, the “Notes”). The Euro Notes will be fully and unconditionally guaranteed by the Company.
The Offerings are expected to close on December 1, 2026. The Notes are being offered pursuant to the shelf registration statement on Form S-3 of the Company and AMS Europe (File No. 333-285032). The Underwriting Agreements contain customary representations, warranties and agreements of the Company and, in the case of the Euro Underwriting Agreement, AMS Europe, and customary conditions to closing, indemnification rights and obligations of the parties and termination provisions. The Underwriters and their affiliates have performed commercial banking, investment banking and advisory services for the Company from time to time for which they have received customary fees and expenses. The Underwriters and their affiliates may, from time to time, engage in transactions with and perform services for the Company and AMS Europe in the ordinary course of their business.
The Company intends to use the net proceeds from the Offerings, together with short-term borrowings and/or borrowings under its credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the Company’s previously announced acquisition of Penumbra, Inc. (“Penumbra”) and to pay related fees and expenses and, to the extent that the net proceeds from the Offerings are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.
On January 14, 2026, the Company entered into an agreement and plan of merger (as such agreement may be amended, modified or supplemented, or any provision thereof waived, the “Merger Agreement”) to acquire Penumbra for a combination of cash and shares of common stock of the Company (the “Penumbra Acquisition”). The Offerings are not conditioned upon the completion of the Penumbra Acquisition, which, if completed, will occur subsequent to the closing of the Offerings. However, if (i) the Penumbra Acquisition is not completed on or before the later of (x) January 14, 2027 (as such date may be extended in accordance with the Merger Agreement to no later than January 14, 2028) and (y) if applicable, the date that is five business days after any later date to which the Company and Penumbra may agree to extend the “Outside Date” in the Merger Agreement as notified to the trustee under the indenture and, if applicable, the paying agent or (ii) the Company and AMS Europe notify the trustee under the indenture and, if applicable, the paying agent that the Company will not pursue completion of the Penumbra Acquisition, the Company and AMS Europe will be required to redeem each series of the USD Notes and the Euro Notes (other than the Floating Rate Notes), respectively, at a special mandatory redemption price equal to 101% of the aggregate principal amount of such series of Notes, plus accrued and unpaid interest, if any, to, but excluding, the special mandatory redemption date (as described in the Notes).
The foregoing descriptions of the USD Underwriting Agreement and the Euro Underwriting Agreement are summaries and are qualified in their entirety by reference to such documents, which are attached as Exhibits 1.1 and 1.2 to this Current Report on Form 8-K, respectively, and both of which are incorporated herein by reference.
Item 2.03 Creation of a Direct Financial Obligation of a Registrant.
The information set forth under Item 1.01 is incorporated herein by reference.
Item 8.01 Other Events.
On November 19, 2026, the Company issued a press release pertaining to the events described in this Current Report on Form 8-K, a copy of which is attached as Exhibit 99.1 hereto and is hereby incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| | | | | | | | |
| Exhibit No. | | Description |
| 1.1 | | Underwriting Agreement, dated as of November 19, 2026, as supplemented by the Terms Agreement, dated November 19, 2026, among Boston Scientific Corporation and the representatives of the several underwriters named therein. |
| 1.2 | | Underwriting Agreement, dated as of November 19, 2026, as supplemented by the Terms Agreement, dated November 19, 2026, among American Medical Systems Europe B.V., Boston Scientific Corporation and the several underwriters named therein. |
| 99.1 | | Press Release issued by Boston Scientific Corporation, dated November 19, 2026. |
| 104 | | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | | | | |
| Date: | November 20, 2026 | BOSTON SCIENTIFIC CORPORATION |
| | | |
| | By: | /s/ Susan Thompson |
| | | Susan Thompson |
| | | Vice President, Chief Corporate Counsel and Assistant Secretary |
Boston Scientific announces pricing of $3.0 billion and €4.25 billion offerings of senior notes
MARLBOROUGH, Mass., November 19, 2026 – Boston Scientific Corporation (the “Company”) (NYSE: BSX) announced today that it has priced a public offering of $3,000,000,000 aggregate principal amount of U.S. dollar-denominated notes (the “USD Offering”), consisting of $1,000,000,000 aggregate principal amount of 5.375% Senior Notes due 2029, $750,000,000 aggregate principal amount of 5.500% Senior Notes due 2031, $750,000,000 aggregate principal amount of 5.750% Senior Notes due 2033 and $500,000,000 aggregate principal amount of 5.875% Senior Notes due 2036 (collectively, the “USD Notes”).
In addition, the Company announced today that American Medical Systems Europe B.V., its indirect wholly owned finance subsidiary, has priced a public offering of €4,250,000,000 aggregate principal amount of euro-denominated notes (the “Euro Offering” and, together with the USD Offering, the “Offerings”), consisting of €500,000,000 aggregate principal amount of Floating Rate Notes due 2028, €500,000,000 aggregate principal amount of 3.875% Senior Notes due 2028, €750,000,000 aggregate principal amount of 4.125% Senior Notes due 2030, €750,000,000 aggregate principal amount of 4.500% Senior Notes due 2034, €1,000,000,000 aggregate principal amount of 4.750% Senior Notes due 2038 and €750,000,000 aggregate principal amount of 5.125% Senior Notes due 2046 (collectively, the “Euro Notes”). The Euro Notes will be fully and unconditionally guaranteed by the Company.
The Offerings are being made pursuant to a registration statement filed with the U.S. Securities and Exchange Commission.
The Offerings are expected to close on December 1, 2026, subject to customary closing conditions. Neither Offering is conditioned upon the completion of the other Offering. The Company intends to use the net proceeds from the Offerings, together with short-term borrowings and/or borrowings under its credit agreement(s) and cash on hand, to finance the cash consideration payable in connection with the acquisition of Penumbra, Inc. (the “Penumbra Acquisition”) and to pay related fees and expenses and, to the extent that the net proceeds from the Offerings are not used for such purposes, for general corporate purposes, which may include, among other things, short term investments, reduction of short term debt, funding of working capital and potential future acquisitions.
The Offerings are not conditioned upon the completion of the Penumbra Acquisition. However, if the Penumbra Acquisition is not completed on or before the applicable special mandatory redemption end date, or if the applicable issuer notifies the trustee that the Company will not pursue completion of the Penumbra Acquisition, each series of the USD Notes and the Euro Notes will be subject to a special mandatory redemption at a redemption price equal to 101% of the aggregate principal amount of such series, plus accrued and unpaid interest, if any, to, but excluding, the special mandatory redemption date.
Nothing herein shall constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to qualification under the securities laws of any such state or jurisdiction. The Offerings are being made by means of a prospectus and related separate preliminary prospectus supplements only. Copies of the prospectus and related preliminary prospectus supplement for the USD Notes, and information concerning the USD Offering, may be obtained by contacting the joint book-running managers for the USD Offering: BofA Securities, Inc., toll-free at 1-800-294-1322; Citigroup Global Markets Inc., toll-free at 1-800-831-9146; or J.P. Morgan Securities LLC, collect at 1-212-834-4533. Copies of the prospectus and related preliminary prospectus supplement for the Euro Notes, and information concerning the Euro Offering, may be obtained by contacting the joint book-running managers for the Euro Offering: Barclays Bank PLC, toll-free at 1-888-603-5847; Citigroup Global Markets Europe AG, toll-free at 1-800-831-9146; or J.P. Morgan SE, collect at +49 69 71240 (for non-U.S. investors) or J.P. Morgan Securities LLC collect at 1-212-834-4533 (for U.S. investors).
About Boston Scientific
Boston Scientific transforms lives through innovative medical technologies that improve the health of patients around the world. As a global medical technology leader for more than 45 years, we advance science for life by providing a broad range of high-performance solutions that address unmet patient needs and reduce the cost of healthcare. Our portfolio of devices and therapies helps physicians diagnose and treat complex cardiovascular, respiratory, digestive, oncological, neurological and urological diseases and conditions. Learn more at www.bostonscientific.com and follow us on LinkedIn.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like “anticipate,” “expect,” “project,” “believe,” “plan,” “estimate,” “intend,” “aim,” “goal,” “target,” “continue,” “hope,” “may” and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not
intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding the proposed Offerings and intended use of proceeds. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These risks and uncertainties, in some cases, have affected and in the future could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the forward-looking statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
Risks and uncertainties that may cause such differences include, among other things: economic conditions, including the impact of foreign currency fluctuations; future U.S. and global political, competitive, reimbursement and regulatory conditions, including changing trade and tariff policies; geopolitical conflicts and tensions; manufacturing, distribution and supply chain disruptions and cost increases; disruptions caused by cybersecurity events, including the impacts of the cybersecurity incident first reported on August 26, 2026 on our operations and financial results; disruptions caused by public health emergencies or extreme weather or other climate change-related events; labor shortages and increases in labor costs; variations in outcomes of ongoing and future clinical trials and market studies; new product introductions and the market acceptance of those products; market competition for our products; expected pricing environment; expected procedural volumes; the closing and integration of acquisitions; demographic trends; intellectual property rights; litigation; financial market conditions; the execution and effect of our prior and new restructuring programs; the execution and effect of our business strategy, including our cost-savings and growth initiatives; our ability to achieve sustainability goals; and future business decisions made by us and our competitors. New risks and uncertainties may arise from time to time and are difficult to predict. All of these factors are difficult or impossible to predict accurately and many of them are beyond our control. For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K, which we may update in Part II, Item 1A. Risk Factors in Quarterly Reports on Form 10-Q that we have filed or will file hereafter. We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions, or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements, except as required by law. This cautionary statement is applicable to all forward-looking statements contained in this press release.
| | |
| CONTACTS: |
| Chanel Hastings |
| Media Relations |
| +1 (508) 382-0288 |
| Chanel.Hastings@bsci.com |
|
| Lauren Tengler |
| Investor Relations |
| +1 (508) 683-4479 |
| BSXInvestorRelations@bsci.com |
|